CN109486715A - A kind of selenium-rich bifidobacterium longum and its preparation method and application - Google Patents
A kind of selenium-rich bifidobacterium longum and its preparation method and application Download PDFInfo
- Publication number
- CN109486715A CN109486715A CN201811491494.2A CN201811491494A CN109486715A CN 109486715 A CN109486715 A CN 109486715A CN 201811491494 A CN201811491494 A CN 201811491494A CN 109486715 A CN109486715 A CN 109486715A
- Authority
- CN
- China
- Prior art keywords
- selenium
- bifidobacterium longum
- preparation
- food
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 63
- 239000011669 selenium Substances 0.000 title claims abstract description 63
- 241001608472 Bifidobacterium longum Species 0.000 title claims abstract description 51
- 229940009291 bifidobacterium longum Drugs 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 40
- 235000013305 food Nutrition 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 21
- 210000004369 blood Anatomy 0.000 claims abstract description 20
- 239000008280 blood Substances 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 210000002966 serum Anatomy 0.000 claims abstract description 15
- 210000000496 pancreas Anatomy 0.000 claims abstract description 13
- 210000004185 liver Anatomy 0.000 claims abstract description 12
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000004060 metabolic process Effects 0.000 claims abstract description 9
- 230000004155 insulin signaling pathway Effects 0.000 claims abstract description 8
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 210000003734 kidney Anatomy 0.000 claims abstract description 7
- 230000003907 kidney function Effects 0.000 claims abstract description 7
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims abstract description 5
- 229940109239 creatinine Drugs 0.000 claims abstract description 5
- 230000006378 damage Effects 0.000 claims abstract description 5
- 208000033679 diabetic kidney disease Diseases 0.000 claims abstract description 5
- 229940091258 selenium supplement Drugs 0.000 claims description 61
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 19
- 239000008103 glucose Substances 0.000 claims description 19
- 239000001963 growth medium Substances 0.000 claims description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 102000004877 Insulin Human genes 0.000 claims description 8
- 108090001061 Insulin Proteins 0.000 claims description 8
- 229940125396 insulin Drugs 0.000 claims description 8
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 6
- 230000037406 food intake Effects 0.000 claims description 6
- 235000012631 food intake Nutrition 0.000 claims description 6
- 229960001471 sodium selenite Drugs 0.000 claims description 6
- 235000015921 sodium selenite Nutrition 0.000 claims description 6
- 239000011781 sodium selenite Substances 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- 230000007170 pathology Effects 0.000 claims description 5
- 230000001934 delay Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 238000007446 glucose tolerance test Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims 1
- 231100000915 pathological change Toxicity 0.000 abstract description 4
- 230000036285 pathological change Effects 0.000 abstract description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 229960001031 glucose Drugs 0.000 description 18
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 17
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 16
- 229960001052 streptozocin Drugs 0.000 description 16
- 239000007924 injection Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 241000186000 Bifidobacterium Species 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 102000008114 Selenoproteins Human genes 0.000 description 2
- 108010074686 Selenoproteins Proteins 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960000673 dextrose monohydrate Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Abstract
The invention belongs to field of biotechnology, a kind of selenium-rich bifidobacterium longum and its preparation method and application is specifically disclosed.Selenium-rich bifidobacterium longum prepared by middle preparation method according to the present invention, it can be applied to preparation to delay in diabetes progression drug or food, specifically include: preparation improves diabetes physical signs and metabolism status, improve diabetes model insulin signaling pathway, improve the pathological change of diabetes liver, pancreas and kidney, improve diabetes serum creatinine and blood urea nitrogen is horizontal, prevents in the application of drug or food of diabetic nephropathy or kidney function damage.
Description
Technical field
The present invention relates to field of biotechnology, and in particular to a kind of selenium-rich bifidobacterium longum and preparation method thereof and is preparing
Delay the application in diabetes progression drug or food.
Background technique
Bifidobacterium is that one kind can be grown naturally in human gi-tract, and host can be protected to resist virus infection
Bacterium category belongs to Gram-positive, non-athletic property, branch anaerobism Pseudomonas.Under normal conditions, Bifidobacterium is by as probiotics
It is digestive using coming.Current scientific research finds and demonstrates the new application of probiotics, i.e., including diabetes
Purposes in terms of metabolic disorder.
Selenium is basic microelement required for human and animal's health, is mainly played an active part in the form of selenoprotein dynamic
In object physiological processes.It is reported that selenium agent can continue to improve the stable state metabolism of glucose, so that glycometabolism process is adjusted, such as sugar
Glycolysis and glucose generate.Therefore, in diabetic, Selenium Supplement agent can reduce plasma glucose levels.Insulin and
There is synergistic effect between selenium, insulin and selenium synergistic treatment can control the blood glucose of diabetes rat.However, epidemic data table
Bright, there are positive correlations between selenium state and diabetes risk.Largely studies have shown that organic selenium is compared with inorganic selenium,
Toxicity is lower, and bioactivity is higher, can be absorbed and utilize rapidly, so it becomes Recent study person's coke of interest
Point.Current study show that bifidobacterium longum can influence the immune function of mice with tumor with Enriching Selenium in the form of selenoprotein.Have
Studies have shown that the dietary supplements containing a variety of probiotics can prevent the raising of diabetic's fasting blood-glucose.Take orally long bifid bar
Bacterium mixture can reduce serum level of glucose, enhance the expression of related protein in insulin signaling pathway, improve diabetes
The fat content of mouse.However, selenium-rich bifidobacterium longum is to streptozotocin (STZ) inducing mouse diabetes model and kidney function
The influence of energy does not have detailed report also.
Summary of the invention
Improvement for solution diabetes existing in the prior art is bad, and easily causes renal function is bad to lack
Point delays diabetes progression the object of the present invention is to provide a kind of selenium-rich bifidobacterium longum and preparation method thereof and in preparation
Drug or food in application.
The present invention is realized by following technical method:
(1) sodium selenite is dissolved in TPY culture medium, obtains the culture medium of TPY containing selenium；
(2) bifidobacterium longum bacterium solution and above-mentioned TPY containing selenium culture medium are mixed, is then seeded into new TPY culture medium, trained
Case culture is supported, the bacterium solution of culture is collected, obtains selenium-rich bifidobacterium longum.
Preferably, the concentration of sodium selenite is 20~30g/mL in the culture medium of TPY containing selenium described in step (1).
Preferably, bifidobacterium longum bacterium solution described in step (2) and the culture medium of TPY containing selenium mixing ratio be 1:20~
30；The condition of the culture are as follows: under anaerobic condition, 37 DEG C of constant incubators are incubated overnight, until OD600 reaches 0.2.
Preferably, the selenium-rich bifidobacterium longum delays the application in diabetes progression drug or food in preparation.
Preferably, the selenium-rich bifidobacterium longum preparation improve diabetes physical signs and metabolism status drug or
Application in food, the diabetes physical signs and metabolism status are fasting blood glucose, weight, serum insulin level, Portugal
Grape sugar tolerance tests (I PTGG), food intake dose, water intake and urine volume.
Preferably, the selenium-rich bifidobacterium longum preparation improve diabetes model insulin signaling pathway drug or
Application in food.
Preferably, the selenium-rich bifidobacterium longum improves the pathological change of diabetes liver, pancreas and kidney in preparation
Drug or food in application.
Preferably, the selenium-rich bifidobacterium longum improves diabetes serum creatinine (Scr) and blood urea nitrogen in preparation
(BUN) application in horizontal drug or food.
Preferably, the selenium-rich bifidobacterium longum is in preparation prevention diabetic nephropathy or the medicine of kidney function damage
Application in object or food.
The invention has the benefit that
(1) selenium-rich bifidobacterium longum processing group is compared with model group, and blood glucose level reduces and mouse weight increases, serum pancreas
The horizontal decline of island element, IPGTT, for 24 hours food intake dose, intake water and urine volume significantly improve.
(2) H&E pathological examination, which shows selenium-rich bifidobacterium longum, can mitigate the pathology lesion of liver and pancreas.
(3) lesions showed mitigates in the pathological section of kidney, and the content of Scr and BUN substantially reduces in serum, shows richness
Protective effect of the selenium bifidobacterium longum to diabetic nephropathy.In selenium-rich bifidobacterium longum processing group, insulin signaling pathway
Correlative protein expression level is higher than model group.
Detailed description of the invention
Figure 1A is the blood glucose and the tendency chart of time before intragastric administration on mice bacterium solution and after injection STZ；
Figure 1B is the weight and the tendency chart of time before intragastric administration on mice bacterium solution and after injection STZ；
Fig. 1 C is the level and the tendency chart of time before intragastric administration on mice bacterium solution with the serum insulin after injection STZ.
Fig. 2 be injectable dextrose monohydrate after time and blood glucose level relational graph.
Fig. 3 A is 1 week and 6 weeks after STZ injection, the column diagram of the food intake dose of each group mouse；
Fig. 3 B is 1 week and 6 weeks after STZ injection, the column diagram of the urine volume of each group mouse；
Wherein, (1 week) normal group of 1-；2- model group (1 week)；3- low dose group (1 week)；4- middle dose group (1 week)；5- high
Dosage group (1 week)；
1 '-normal group (6 weeks)；2 '-model groups (6 weeks)；3 '-low dose groups (6 weeks)；4 '-middle dose groups (6 weeks)；5 '-is high
Dosage group (6 weeks).
Fig. 4 is the figure of the urea nitrogen levels of mouse in each experimental group.
Fig. 5 is influence schematic diagram of the selenium-rich bifidobacterium longum to insulin signaling pathway.
Fig. 6 is influence schematic diagram of the selenium-rich bifidobacterium longum to pancreas (A) and liver (B) pathomorphism.
Fig. 7 is that each experimental group nephridial tissue checks comparison diagram.
In figure,##Indicate value < 0.01 P,###It indicates P value < 0.001, n=8 (representing 8 samples), compared with normal group；* table
Show that P value < 0.05, * * indicates P value < 0.01, n=8, compared with model group.
Specific embodiment
With reference to embodiment, the present invention is described in further detail.
Embodiment 1
(1) preparation of bacterium solution
Bifidobacterium longum is in 37 DEG C of TPY Anaerobic culturels.Sodium selenite is dissolved in 200ml TPY culture medium to final
Concentration is 25g/mL (concentration for having attempted sodium selenite is respectively 20,22.5,25,27.5,30g/mL, and effect is close)；It will grow
Bifidobacterium bacterium solution, by taken bacterium solution amount: (having attempted bifidobacterium longum bacterium solution and containing seleno culture medium containing seleno culture medium=1:25
Mass ratio is respectively 1:20,1:22.5,1:25,1:27.5,1:30, and effect is close) it is inoculated into new TPY culture medium；Anaerobism item
It under part, is incubated overnight in 37 DEG C of constant incubators, until OD600 reaches 0.2 or more, collects the bacterium solution of culture；3500rpm
Under revolving speed, 4 DEG C of centrifugation 5min are cleaned 3 times with 5% G/NS.Collected bacterium solution is resuspended in the 13% of 0.1mL
It is spare in skim milk.
(2) zoopery
Mouse grows under 21 DEG C of room temperature, 12h Light-Dark alternate environment, freely takes the photograph water and ingests.Normal group mouse note
Penetrate 100 μ L of citrate.The foundation of diabetic model group mouse method particularly includes: mouse fasting 12h, free water are molten by STZ
In cold lemon acid buffering (pH=4.5) the extremely final concentration of 50mg/kg of 0.1M, awards within continuous 5 days mouse and inject 100 μ L STZ.
1 week after diabetic model group mouse last time injection STZ, mouse fasting blood glucose level, blood glucose level are measured using blood glucose meter
>=11.1mM is modeling success.8 weeks after last time injection STZ, mouse blood sugar level and weight are monitored weekly.
50 4-5 week old male C57BL/6 mouse are randomly divided into 5 groups: grouping: normal group, model group, and the long bifid of selenium-rich
Bacillus low dose group (0.75 × 1010A/kg), middle dose group (1.5 × 1010A/kg), high dose group (3.0 × 1010A/
kg).Treatment group, the daily 100 μ L of stomach-filling selenium-rich bifidobacterium longum of every mouse, stomach-filling time are 4 weeks.Normal group is given once daily
100 μ L, 13% skim milk.Mouse gives selenium-rich bifidobacterium longum the 25th day, and mouse fasting 12 hours, continuous 5 days abdominal cavities note
Penetrate STZ.Last time injection puts to death mouse after STZ 8 weeks.STZ injection after the 1 to 8th week in, monitoring mouse blood sugar level and
Weight (such as Fig. 1).The the 1st and 6 week after STZ injection, mouse is put into mouse metabolism cage, collects mouse food intake dose for 24 hours
With urine volume (such as Fig. 3 A~3B).After the 7th week progress glucose tolerance test of STZ injection, mouse overnight starvation, intraperitoneal injection
Glucose (1.0g/kg), injection 0,15,30,60,90min in tail vein take blood, detect blood-sugar content (such as Fig. 2) with blood glucose meter.
At the 8th week of STZ injection, serum insulin level is measured with mouse islets element ELISA kit, measures serum urea nitrogen level
(such as Fig. 4).
As shown in Figure 1, selenium-rich bifidobacterium longum administration group (including low dose group, middle dose group and high dose group) and model
Group is compared, and administration group fasting blood glucose level is lower than model group, and has dose-dependence.Weight and blood glucose level have equally
Trend.
As shown in Figure 2, after model group mouse injectable dextrose monohydrate, the level of blood sugar recovery is remarkably decreased, the results showed that in richness
The Scavenging activity to glucose in vivo is improved after the administration of selenium bifidobacterium longum.
By Fig. 3 A~3B it is found that mouse is put into metabolic cage the 1st week and the 6th week after STZ injection, mouse 24 is recorded
Hour food intake dose and urine volume；Compared with model group, selenium-rich bifidobacterium longum administration group significantly reduces the metabolism shape of mouse
Condition；Also there is same variation in selenium-rich bifidobacterium longum administration group water intake.
As shown in Figure 4, mice serum urea nitrogen levels are measured, as a result, it has been found that selenium-rich bifidobacterium longum processing group and model
Group mouse is compared, and level reduces；When measuring mice serum creatinine, also there is same variation in level.The above pathology knot
Fruit and serum measurement result show that selenium-rich bifidobacterium longum can improve the renal function impaired because of diabetes.
(3) Western blotting is tested
Murine liver tissue is homogenized in cell pyrolysis liquid, after cracking 30min on ice, under 12000r/min revolving speed, and 4 DEG C of centrifugations
10min collects supernatant, and detects protein concentration with BCA kit, and adjustment protein concentration is consistent, and 5 × loading is added
Buffer simultaneously boils sample 5min in boiling water bath, takes 30g total protein to carry out SDS-PAGE electrophoresis, and in transferring film to pvdf membrane.Through 5%
Film is washed using PBST after skim milk room temperature closing 1.5h.With following antibody anti-GSK-3 β, anti-pGSK-3 β, anti-
AKT, anti-pAKT and GAPDH primary antibody dilution (1: 1000) are incubated for, and 4 DEG C overnight.PBST reuses secondary antibody after washing film
Dilution (1: 5000) is incubated at room temperature 0.5-1h, is developed the color after PBST washes film using ECL developing solution, Full-automatic chemiluminescence analysis
(such as Fig. 5) is imaged in instrument (Tanon).
As shown in Figure 5, compared with model group, the expression of pAKT is dramatically increased in liver, and pGSK-3 β expression substantially reduces；
The expression of insulin signaling pathway GAP-associated protein GAP increases, and insulin signaling pathway is activated, and improves liver after showing administration
The sensibility of insulin signaling.
(4) H&E Coloration experiment
In order to observe liver, pancreas and the morphological change of kidney, H&E staining procedure is as follows: liver, pancreas and kidney group
It knits and is placed in 4% paraformaldehyde fixed stay overnight；Routine paraffin wax embedding, 5 μm of slices；Slice is conventional to be dewaxed with dimethylbenzene, through at different levels
Ethyl alcohol is extremely washed.It is transparent: respectively to impregnate 5min in dimethylbenzene I, dimethylbenzene II, be dehydrated: dehydrated alcohol I, dehydrated alcohol II, 95% wine
Essence, 80% alcohol, 75% alcohol, each 5min；Indigo plant is returned in flowing water flushing after haematoxylin redyes 2min, and tap water impregnates 15min or temperature
Water (about 50 DEG C) 5min；Yihong liquid 2min is set, tap water rinses.Dehydration: 75% alcohol, 80% alcohol, 95% alcohol, anhydrous second
Alcohol I, each 5min of dehydrated alcohol II.It is transparent: respectively to impregnate 5min in dimethylbenzene I, dimethylbenzene II, dry 3min.Mounting: it is added dropwise neutral
Then resin mounting takes clean coverslip, is carefully added on mounting medium, slowly flatten in tissue, keep cover plate position suitable
In.Microscopically observation, simultaneously long-term preservation (such as Fig. 6 and 7) of taking pictures.
It will be appreciated from fig. 6 that liver and pancreas carry out pathological analysis discovery, selenium-rich bifidobacterium longum and mould through H&E coloration result
Pathological change has significant difference between type group.As shown in Figure 6A, normally group mouse does not have apparent pathological change；Model group pancreas
Island cell has cell infiltration；Low dose group is only observed containing a large amount of fatty vacuole in pancreatic tissue, as selenium-rich is long double
The dosage of discrimination bacillus increases, and the fatty vacuole quantity in pancreas group is reduced.As shown in Figure 6B, liver cell has a large amount of inflammation in model group
Cellular infiltration, and with the increase of selenium-rich bifidobacterium longum dosage, the degree of cell infiltration gradually mitigates.In short, selenium-rich is long
After Bifidobacterium administration, the tempo of liver and Pancreas pathology damage slows down.
As shown in Figure 7, nephridial tissue inspection shows that visible glomerulus blister cavities disappears in model group renal tissue, sphere and capsule
Wall is adhered, a large amount of coagulation necrosis in glomerulus, in glomerulus red deposit with selenium-rich bifidobacterium longum dosage increase
And gradually weaken.
The present invention also attempt document it has been reported that Bifidobacterium conventional medicine or food making method and drug or
Food formulation method is applied to selenium-rich bifidobacterium longum, also all produces and preferably delays diabetes progression and improvement diabetes
Physical signs and metabolism status, the pathology change for improving diabetes insulin signal path, improvement diabetes liver, pancreas and kidney
Change, the effect of prevention diabetic nephropathy or kidney function damage, improvement diabetes serum creatinine and blood urea nitrogen；The present invention
Also attempt as routine treating diabetes or prophylactic agent or food, by selenium-rich bifidobacterium longum by with conventional diabetes
Drug or food and treatment method use in conjunction are treated or prevented, treating diabetes or preventive effect can be further increased.
Particular embodiments described above has carried out further in detail the purpose of the present invention, technical scheme and beneficial effects
It describes in detail bright, it should be understood that the above is only a specific embodiment of the present invention, is not intended to restrict the invention, it is all
Within the spirit and principles in the present invention, any modification, equivalent substitution, improvement and etc. done should be included in guarantor of the invention
Within the scope of shield.
Claims (10)
1. a kind of preparation method of selenium-rich bifidobacterium longum, which comprises the steps of:
(1) sodium selenite is dissolved in TPY culture medium, obtains the culture medium of TPY containing selenium；
(2) bifidobacterium longum bacterium solution and above-mentioned TPY containing selenium culture medium are mixed, is then seeded into new TPY culture medium, incubator
Culture, collects the bacterium solution of culture, obtains selenium-rich bifidobacterium longum.
2. a kind of preparation method of selenium-rich bifidobacterium longum according to claim 1, which is characterized in that institute in step (1)
The concentration for stating sodium selenite in the culture medium of TPY containing selenium is 20~30g/mL；Bifidobacterium longum bacterium solution described in step (2) and contain selenium
The ratio of TPY culture medium mixing is 1:20~30；The condition of the culture are as follows: under anaerobic condition, 37 DEG C of constant incubators are stayed overnight
Culture, until OD600 reaches 0.2.
3. the selenium-rich bifidobacterium longum of preparation according to the method for claim 1.
4. selenium-rich bifidobacterium longum according to claim 3 delays answering in diabetes progression drug or food in preparation
With.
5. the medicine that selenium-rich bifidobacterium longum according to claim 3 improves diabetes physical signs and metabolism status in preparation
Application in object or food, the diabetes physical signs and metabolism status are fasting blood glucose, weight, serum insulin water
Flat, glucose tolerance test, food intake dose, water intake and urine volume.
6. the medicine that selenium-rich bifidobacterium longum according to claim 3 improves diabetes model insulin signaling pathway in preparation
Application in object or food.
7. the pathology that selenium-rich bifidobacterium longum according to claim 3 improves diabetes liver, pancreas and kidney in preparation
The drug of variation or the application in food.
8. selenium-rich bifidobacterium longum according to claim 3 improves diabetes serum creatinine in preparation and blood urea nitrogen is horizontal
Drug or food in application.
9. selenium-rich bifidobacterium longum according to claim 3 is in preparation prevention diabetic nephropathy or kidney function damage
Drug or food in application.
10. a kind of selenium-rich bifidobacterium longum according to claim 3 treats or prevents drug in preparation and conventional diabetes
Or the application of food conjunctive use delayed in diabetes progression drug or food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811491494.2A CN109486715B (en) | 2018-12-07 | 2018-12-07 | Selenium-enriched bifidobacterium longum and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811491494.2A CN109486715B (en) | 2018-12-07 | 2018-12-07 | Selenium-enriched bifidobacterium longum and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109486715A true CN109486715A (en) | 2019-03-19 |
| CN109486715B CN109486715B (en) | 2022-07-15 |
Family
ID=65709517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811491494.2A Active CN109486715B (en) | 2018-12-07 | 2018-12-07 | Selenium-enriched bifidobacterium longum and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109486715B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109576176A (en) * | 2018-12-07 | 2019-04-05 | 江苏靶标生物医药研究所有限公司 | A kind of nanometer selenium bifidobacterium longum and its preparation method and application |
| CN110408552A (en) * | 2019-07-08 | 2019-11-05 | 牡丹江灵泰药业股份有限公司 | Se-enriched yeast is preparing the application in the antidote of liver renal toxicity caused by cinnabar |
| CN110638841A (en) * | 2019-09-25 | 2020-01-03 | 山东艾克韦生物技术有限公司 | Probiotics and prebiotics compound preparation, preparation method and application thereof |
| CN112807328A (en) * | 2021-02-26 | 2021-05-18 | 江苏德禧生物科技有限公司 | Application of selenium-rich probiotics in preparation of medicine for treating and/or preventing radiation liver injury |
| CN112807438A (en) * | 2021-02-26 | 2021-05-18 | 江苏德禧生物科技有限公司 | Combined medicine composition for type 2 diabetes and liver injury and application thereof |
| CN113293113A (en) * | 2021-06-21 | 2021-08-24 | 美益添生物医药(武汉)有限公司 | Bifidobacterium longum MI-186 and application thereof |
| CN113512520A (en) * | 2021-04-29 | 2021-10-19 | 右江民族医学院 | Chromium-and zinc-rich acetobacter and preparation method and application thereof |
| CN115990193B (en) * | 2022-08-17 | 2024-04-19 | 北京农学院 | Application of bifidobacterium animalis in gestational hyperglycemia |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1555815A (en) * | 2004-01-10 | 2004-12-22 | 内蒙古双奇药业股份有限公司 | Method of bological transforming selenium using bacillus bifidus and its product |
| CN101310606A (en) * | 2007-05-24 | 2008-11-26 | 大连森佰澳科技有限公司 | Liquid milk products containing bifidobacteria function signal and prebiotics |
| CN103619343A (en) * | 2010-12-07 | 2014-03-05 | 高等科学研究委员会 | Bifidobacterium cect 7765 and use thereof in the prevention and/or treatment of excess weight, obesity and related pathologies |
| CN104770739A (en) * | 2009-06-19 | 2015-07-15 | 杜邦营养生物科学有限公司 | Bifidobacteria for treating diabetes and related conditions |
| CN104884610A (en) * | 2012-12-20 | 2015-09-02 | 热尔韦·达诺尼公司 | Use of bifidobacterium animalis for treating or preventing body weight gain and insulin resistance |
| CN106617096A (en) * | 2017-02-15 | 2017-05-10 | 中国农业大学 | Bifidobacterium capable of enhancing pancreatic function and application of bifidobacterium |
| CN107772477A (en) * | 2017-11-27 | 2018-03-09 | 内蒙古普泽生物制品有限责任公司 | A kind of compound probiotic powder preparation rich in selenium and preparation method thereof |
-
2018
- 2018-12-07 CN CN201811491494.2A patent/CN109486715B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1555815A (en) * | 2004-01-10 | 2004-12-22 | 内蒙古双奇药业股份有限公司 | Method of bological transforming selenium using bacillus bifidus and its product |
| CN101310606A (en) * | 2007-05-24 | 2008-11-26 | 大连森佰澳科技有限公司 | Liquid milk products containing bifidobacteria function signal and prebiotics |
| CN104770739A (en) * | 2009-06-19 | 2015-07-15 | 杜邦营养生物科学有限公司 | Bifidobacteria for treating diabetes and related conditions |
| CN104784694A (en) * | 2009-06-19 | 2015-07-22 | 杜邦营养生物科学有限公司 | Bifidobacteria for treating diabetes and related conditions |
| CN103619343A (en) * | 2010-12-07 | 2014-03-05 | 高等科学研究委员会 | Bifidobacterium cect 7765 and use thereof in the prevention and/or treatment of excess weight, obesity and related pathologies |
| CN104884610A (en) * | 2012-12-20 | 2015-09-02 | 热尔韦·达诺尼公司 | Use of bifidobacterium animalis for treating or preventing body weight gain and insulin resistance |
| CN106617096A (en) * | 2017-02-15 | 2017-05-10 | 中国农业大学 | Bifidobacterium capable of enhancing pancreatic function and application of bifidobacterium |
| CN107772477A (en) * | 2017-11-27 | 2018-03-09 | 内蒙古普泽生物制品有限责任公司 | A kind of compound probiotic powder preparation rich in selenium and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| GORU SANTOSH KUMAR等: "Selenium nanoparticles involve HSP-70 and SIRT1 in preventing the progression of type 1 diabetic nephropathy", 《CHEMICO-BIOLOGICAL INTERACTIONS》 * |
| JIN JIN CHEN等: "Bifidobacterium longum supplementation improved high-fat-fed-induced metabolic syndrome and promoted intestinal Reg I gene expression", 《EXPERIMENTAL BIOLOGY AND MEDICINE》 * |
| THI KIM CHUNG LE等: "Oral administration of Bifidobacterium spp. improves insulin resistance, induces adiponectin, and prevents inflammatory adipokine expressions", 《BIOMEDICAL RESEARCH》 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109576176A (en) * | 2018-12-07 | 2019-04-05 | 江苏靶标生物医药研究所有限公司 | A kind of nanometer selenium bifidobacterium longum and its preparation method and application |
| CN110408552B (en) * | 2019-07-08 | 2023-04-07 | 牡丹江灵泰药业股份有限公司 | Application of selenium-enriched yeast in preparation of detoxifying drug for liver and kidney toxicity caused by cinnabar |
| CN110408552A (en) * | 2019-07-08 | 2019-11-05 | 牡丹江灵泰药业股份有限公司 | Se-enriched yeast is preparing the application in the antidote of liver renal toxicity caused by cinnabar |
| CN110638841A (en) * | 2019-09-25 | 2020-01-03 | 山东艾克韦生物技术有限公司 | Probiotics and prebiotics compound preparation, preparation method and application thereof |
| CN110638841B (en) * | 2019-09-25 | 2024-02-20 | 山东艾克韦生物技术有限公司 | Probiotics and prebiotics composite preparation, preparation method and application thereof |
| CN112807328A (en) * | 2021-02-26 | 2021-05-18 | 江苏德禧生物科技有限公司 | Application of selenium-rich probiotics in preparation of medicine for treating and/or preventing radiation liver injury |
| CN112807328B (en) * | 2021-02-26 | 2023-04-11 | 江苏德禧生物科技有限公司 | Application of selenium-rich probiotics in preparation of medicine for treating and/or preventing radiation liver injury |
| CN112807438A (en) * | 2021-02-26 | 2021-05-18 | 江苏德禧生物科技有限公司 | Combined medicine composition for type 2 diabetes and liver injury and application thereof |
| CN113512520A (en) * | 2021-04-29 | 2021-10-19 | 右江民族医学院 | Chromium-and zinc-rich acetobacter and preparation method and application thereof |
| CN113512520B (en) * | 2021-04-29 | 2022-04-26 | 右江民族医学院 | Chromium-and zinc-rich acetobacter and preparation method and application thereof |
| CN113293113B (en) * | 2021-06-21 | 2022-07-29 | 美益添生物医药(武汉)有限公司 | Bifidobacterium longum MI-186 and application thereof |
| CN113293113A (en) * | 2021-06-21 | 2021-08-24 | 美益添生物医药(武汉)有限公司 | Bifidobacterium longum MI-186 and application thereof |
| CN115990193B (en) * | 2022-08-17 | 2024-04-19 | 北京农学院 | Application of bifidobacterium animalis in gestational hyperglycemia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109486715B (en) | 2022-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109486715A (en) | A kind of selenium-rich bifidobacterium longum and its preparation method and application | |
| Barazzoni et al. | Insulin resistance in obesity: an overview of fundamental alterations | |
| Du et al. | Supplementation of inulin with various degree of polymerization ameliorates liver injury and gut microbiota dysbiosis in high fat-fed obese mice | |
| CN108103017B (en) | The application of the isolation and purification method and people's umbilical cord mesenchymal stem cells excretion body of people's umbilical cord mesenchymal stem cells excretion body | |
| Li et al. | Effect of Lactobacillus plantarum NCU116 on loperamide-induced constipation in mice | |
| Roager et al. | Diet‐derived microbial metabolites in health and disease | |
| CN109576176A (en) | A kind of nanometer selenium bifidobacterium longum and its preparation method and application | |
| CN115216422B (en) | Lactobacillus rhamnosus and application thereof | |
| Feng et al. | Major yolk protein from sea cucumber (Stichopus japonicus) attenuates acute colitis via regulation of microbial dysbiosis and inflammatory responses | |
| Yuan et al. | Hypoglycemic effect of nobiletin via regulation of islet β-cell mitophagy and gut microbiota homeostasis in streptozocin-challenged mice | |
| CN107184622A (en) | The total phenolic glycoside of moringa seeds and its application in medicine and health products is prepared | |
| CN109200064A (en) | The purposes of animal bifidobacteria A6 in medicine preparation | |
| Han et al. | Immunomodulatory effect of Lycium barbarum polysaccharides against liver fibrosis based on the intelligent medical internet of things | |
| Zhu et al. | Nuciferine ameliorates high‐fat diet‐induced disorders of glucose and lipid metabolism in obese mice based on the gut–liver axis | |
| Busman et al. | Kersen (Muntingia calabura L.) Ethanol Extract Repairs Pancreatic Cell Damage, Total Coliforms, and Lactic Acid Bacteria in Hyperglycemic Mice. | |
| Mellor et al. | Effect of cocoa in diabetes: the potential of the pancreas and liver as key target organs, more than an antioxidant effect? | |
| CN101204573B (en) | Medicine foe diabetes mellitus | |
| CN109498634A (en) | Application of the brown alga oligose in preparation inflammatory enteropathy drug | |
| Zhou et al. | Fuzhuan brick tea supplemented with areca nuts: Effects on serum and gut microbiota in mice | |
| Bazekin et al. | Morphofunctional assessment of the glycyrrhizinic acid effect on myocardium of rats under adrenaline loading. | |
| CN101822660B (en) | Application of rhein compound or its salt in preparing drugs preventing and curing hypofunction of islet beta cell | |
| CN115125163B (en) | Lactobacillus casei and application thereof | |
| Zou et al. | Dietary inulin alleviated constipation induced depression and anxiety-like behaviors: Involvement of gut microbiota and microbial metabolite short-chain fatty acid | |
| Liao et al. | Extracellular polysaccharides from Sporidiobolus pararoseus alleviates rheumatoid through ameliorating gut barrier function and gut microbiota | |
| Li et al. | Toxicological effects of diclofenac sodium in duodenum tissue and intestinal microorganisms of chickens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |